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Abstract 82 
Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can 83 
enable economists to include economic information on health care provision. Application of economic evidence in 84 
CPGs, and its integration into clinical practice and national decision making is hampered by objections from 85 
professions, paucity of economic evidence or lack of policy commitment. The use of state-of-art economic 86 
methodologies will improve this. 87 
Economic evidence can be graded by 'checklists' to establish the best evidence for decision making given 88 
methodological rigor. New economic evaluation checklists, Multi-Criteria Decision Analyses (MCDA) and other 89 
decision criteria enable health economists to impact on decision making world-wide. We analyse the methodologies for 90 
integrating economic evidence into CPG agencies globally, including the Agency of Health Research and Quality 91 
(AHRQ) in the USA, National Health and Medical Research Council (NHMRC) and Australian political reforms. The 92 
Guidelines and Economists Network International (GENI) Board members from Australia, UK, Canada and Denmark 93 
presented the findings at the conference of the International Health Economists Association (IHEA)  and we report 94 
conclusions and developments since.   95 
The Consolidated Guidelines for the Reporting of Economic Evaluations  (CHEERS) 24 item check list can be used by 96 
AHRQ, NHMRC, other CPG and health organisations, in conjunction with the Drummond ten-point check list and a 97 
questionnaire that scores that checklist for grading studies, when assessing economic evidence. Cost-effectiveness 98 
Analysis  (CEA) thresholds, opportunity cost and willingness-to-pay (WTP) are crucial issues for decision rules in CEA 99 
generally, including end-of-life therapies. Limitations of inter-rater reliability in checklists can be addressed by 100 
including more than one assessor to reach a consensus, especially when impacting on treatment decisions. We identify 101 
priority areas to generate economic evidence for CPGs by NHMRC, AHRQ, and other agencies. The evidence may 102 
cover demand for care issues such as involved time, logistics, innovation price, price sensitivity, substitutes and 103 
complements, WTP, absenteeism and presentism. Supply issues may include economies of scale, efficiency changes, 104 
and return on investment. Involved equity and efficiency measures may include cost-of-illness, disease burden, quality-105 
of-life, budget impact, cost-effective ratios, net benefits and disparities in access and outcomes.. 106 
Priority setting remains essential and trade-off decisions between policy criteria can be based on MCDA, both in 107 
evidence based clinical medicine and in health planning. 108 
 109 
Introduction  110 
 111 
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Economic evidence is becoming influential in health technology assessment (HTA) world-wide. However, most health 112 
care practices and procedures are not subjected to HTAs, thereby limiting the impact of economic evidence. CPGs offer 113 
the potential for economists to be centrally involved in increasing the cost-effectiveness of health care provision. 114 
However, examples of the use of economic evidence in such guidelines, and the subsequent integration of such 115 
evidence into clinical practice and national decision making are limited. This may be because of resistance from the 116 
professions, paucity of economic evidence or lack of policy commitment.  117 
Important components of the evidence used in the development of CPGs  include the use of systematic reviews of the 118 
literature, decision rules, WTP, opportunity costs, and end of life/social value judgement along with techniques to grade 119 
the economic evidence. Such evidence can be graded by guidelines or 'checklists' to establish which evidence should be 120 
used to  inform decisions based on the rigor of the methodology. New developments in all of these areas are cutting 121 
edge techniques that provide a platform for improved contribution by health economists in decision making world-wide 122 
and are considered in this paper. The principal purpose of this paper is to address the implications of these 123 
methodologies for the integration of economic evidence into CPG  agencies world-wide and their implications for  124 
Australian reforms by the Parliament, governments and health services.  These issues were discussed by Board 125 
members of the Guidelines and Economists Network International
1
 (GENI) in presentations at the 9th IHEA World 126 
Congress. 127 
The GENI is an international association which enables health economists, epidemiologists, clinicians and medical 128 
experts  world-wide to work with prominent international bodies, health services and governments. GENI's agenda is to 129 
facilitate the effective integration of CPGs, economic and clinical evidence into national decision making and clinical 130 
practice in the health sector. GENI aims to forge linkages with bodies that set the standards for appropriate treatment 131 
under different conditions that may link to contracts or regulatory processes such as insurers and national government 132 
funding systems. Linkages to Evidence Based Medicine (EBM), service delivery and related government regulatory and 133 
funding systems are central.  GENI’s has twelve international board members and a large twenty nine member  134 
management team comprising  CEO, Medical Advisory Committee, Directors, senior managers and researchers, with 135 
over 830  GENI LinkedIn Group affiliates.  136 
 137 
At the 9th IHEA Congress, five of GENI's Board members from America, UK, Australia, Canada and Denmark 138 
discussed new methodologies and economic guidelines or 'checklists' for incorporating economic evidence into CPGs, 139 
clinical practice and national decision making. The session considered guidelines recently developed for the conduct 140 
                                                          
1
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and reporting of economic evaluations. These guidelines assess studies for decision-making in technology assessment 141 
for reimbursement or developing CPGs.  The session also discussed use of  CEA evidence in CPG processes  in 142 
Australia by NHMRC,  three Local Hospital Networks (LHNs) in Victoria and implications  for related national and 143 
state health policy reforms led by the Council of Australian Governments (COAG) and reviewed by the Australian 144 
Parliament.An impetus for the international discussion at IHEA was a request from the NHMRC for input from GENI 145 
about the Council's  review of its processes to develop and approve guidelines in Australia using the costs and benefits 146 
evidence and also  socio-economic evidence. The focus on  these Evidence Based Medicine (EBM) approaches  147 
involving CPGs and CEA evidence has also been an important feature in  some reforms  by the Australian Parliament, 148 
Governments and health services. The methodologies discussed in this paper may further assist this reform agenda, 149 
along with the deliberations of the NHMRC and other regulatory bodies that approve CPGs world-wide. 150 
Firstly, we discuss  Australian health policy reforms  in   Commonwealth-State  health agreements  involving,  inter 151 
alia,  national  implementation of  LHN governance structures and hospital Activity Based Funding (ABF)   based on 152 
the Victorian model.  Recommendations  were  provided to COAG and the Senate based on Victorian evaluations of  153 
applications of   NHMRC's CPG methods using CEA in  Victorian LHNs and  the risk adjustment of ABF, given  154 
relevance to legislation  for health agreements and related authorities.  The Senate also considered  reforms  for 155 
palliative care, rural health and the Aged Care Quality Agency  and  recommendations were submitted to the  Senate 156 
about crucial CPG and CEA issues.   COAG's 2016  Heads of Agreements on Public Hospital Funding will reduce ABF 157 
for specified adverse events, ineffective or harmful treatments and  readmissions from  July 2017. Recommendations to 158 
the Senate about  risk adjusting ABF and measurements of quality outcomes and disseminating  NHMRC's  EBM 159 
methods Australia-wide are also discussed. The NHMRC's CPG development  process review is then considered.  160 
 161 
That is followed by  consideration of the CHEERS Task Force which has consolidated  guidelines for assessing health 162 
economic evaluation  studies and recently published a consensus statement, along with the checklist. Recent  163 
developments for MCDA  that broaden the objectives of evaluation in health care are considered  along with  the 164 
International Society for Pharmacoeconomics and Outcomes Research's  (ISPOR)  MCDA Emerging Good 165 
Practices Task Force that has developed a common deﬁnition for MCDA in health care and good practice 166 
guidelines for conducting MCDA.  The Hopkins Review is then discussed  which  examines if and how economic 167 
evidence impacts on health policy, including clinical guidelines,  in the USA.   It also examines  the strengths and 168 
weaknesses of existing checklists used to assess best practices in economic evaluations. The review of  studies also  169 
addresses the use of economic outcomes in policy and decision making.  Finally, we  conclude with implications of 170 
these deliberations world-wide for  health services,   governments and agencies that develop CPGs such as National 171 
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Institute of Health and Care Excellence (NICE), US Guidelines clearing house,NHMRC and the USA Centre for 172 
Disease Control and Prevention (CDC). 173 
 174 
Review 175 
Lessons for Australian Parliament, National Health and Medical Research Council, Governments and Health 176 
Services  177 
Australian Commonwealth-State Health Agreements and Reforms 178 
 179 
In Australia, there are several agreements between Commonwealth and State governments through the Council of 180 
Australian Governments (COAG),  that specify health policy and reform directions, including  the National Healthcare 181 
Agreement (NHA), the National Health Reform Agreement (NHRA), National Partnership Agreements  and the  182 
Intergovernmental Agreement on Federal Financial Relations.  Further, the  April 2016  Heads of Agreement on Public 183 
Hospital Funding  forms the basis of negotiations leading towards a time-limited addendum of the NHRA, in the form 184 
of an additional schedule, to commence on 1 July 2017.  185 
 186 
This suite of Agreements is designed to set out the architecture for a nationally unified and locally controlled health 187 
system.  They also encourage improved quality of care and  the cost-effective use of  guidelines, clinical pathways and 188 
other EBM initiatives (COAG 2011) [1]. 189 
 190 
Antioch briefed COAG  during 2008, 2009 and  2010 about the new health agreements. She also briefed the Australian 191 
Senate from 2010 to 2013  on  COAG Agreements and related authorities  and, in 2016,  on new COAG Heads of 192 
Agreements. Some briefs  included evidence that implementing NHMRC methodologies for CPG implementation with 193 
economic and clinical evidence  in Victorian LHNs resulted in cost effective service provision in the context of ABF.  194 
She recommended the development of State Centres of EBM Health Services and Workforce Redesign, use of NHMRC 195 
and international methods with economic and clinical evidence. an International Centre of EBM and Health Economics 196 
and the need for adequate risk adjustment of ABF   (Antioch 2008, 2009, 2010a) [2, 3 ,4].   197 
Antioch's (2008) [2]  COAG brief addressed a reform agenda for the 2009 Australian Healthcare Agreements (AHA) 198 
re-negotiation involving two areas. Firstly, she proposed new state centres to  integrate the economic and clinical 199 
evidence and CPGs into clinical practice using methods by  the NHMRC (1999, 2000a, 2000b, 2000c, 2001) (5, 6, 7, 8, 200 
9), Antioch Jennings and Botti (2002) [10], Drummond, Schulpher Torrance et al (2005) [11]  and  organisations such 201 
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as GENI.  Secondly, she argued  the equity of the AHCA formulae and index  can be improved using risk adjustment to 202 
align funding with health need by using either Diagnostic Cost Group – Hierarchical Condition Categories (DCG-HCC) 203 
relative risk scores or Diagnostic Related Group (DRG) cost weights,  Evidence she published in European Journal of 204 
Health Economics  concerning risk adjustment requirements for the ABF formulae in Victoria  relating to severity 205 
markers for state-wide referral services eg transplantation, major trauma was also referenced [2,  12]. 206 
Antioch's (2009)  [3] COAG brief outlined national cost savings of $273.524m pa  (2006 prices)  and $1,367.620m over 207 
five years via implementation of the proposed State Centres, modelled on cost savings achieved by reductions of 208 
adverse events and length of stay in the Victorian hospital experience. That brief attached advice from the Northern 209 
Territory (NT) Health Minister who expressed interest in risk adjustment for ABF implementation given the 210 
demographic and geography of NT are such that the use of a standard Australian profile runs a severe risk of the 211 
jurisdiction being disadvantaged (Antioch 2009) [3]. The ABF formulae subsequently developed  by the Australian 212 
Government included a risk adjustment to the formulae called 'indigenous adjustment' which still remains along with 213 
other adjustments  (IHPA, 2015) [13] 214 
 215 
Antioch's  COAG brief (2010a),  which was also published by  the Senate Standing Committee on Finance and Public 216 
Administration Inquiry into COAG  Reforms relating to Health and Hospitals [4],  stated that some Health Ministers  217 
advised that their Departments were considering her  reform proposals for their implementation of the National Health 218 
Agreements and Partnership programs, with one large jurisdiction indicating  that the State planned to introduce a State 219 
Centre similar to her proposed State Centres.  The brief also recommended the establishment of an International Centre 220 
of Evidence Based Medicine and Health Economics  221 
Antioch's COAG and Senate submissions indicated that the 'State Centres' recommendation arose from national 222 
stakeholder engagement during her 2007 presentations in all Australian States and Territories and NZ about the 223 
implementation and evaluation of the initiatives she led in the Victorian  LHNs and  subsequent liaison with the Federal 224 
Health Ministers' Office. The national presentations were sponsored by the Australian Health Care and Hospital 225 
Association and the Women's and Children's Hospital Australasia in the context of the renegotiation of National Health 226 
Agreements.  She provided a Cost Benefit Analysis (CBA)  of national implementation of the State Centres  in her 227 
invited submission to the Senate Inquiry concerning the establishment of the National Health Performance Authority 228 
and  also the Independent Hospital Pricing Authority   which calculated net benefits of $269.6m per annum  (2006 229 
prices) (Antioch, 2011a, 2011b) [14, 15].  The CBA was modelled on the evaluation of  the Victorian LHN  initiatives. 230 
Many features of the national reforms by COAG, and under consideration by then Australian Parliament, were based on 231 
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the Victorian health system including ABF and new hospital network governance through LHNs. Evidence of cost 232 
effective EBM implementation in Victoria was of interest. 233 
 234 
Australian Parliament Inquiries on Health Agreement Legislation and Health Policy Reforms 235 
Parliamentary Inquiries since 2010 made recommendations about policy and legislation to implement elements of the 236 
Health Agreements and other health policy.  The  Senate Report on the Federal Finance (National Health and Hospitals 237 
Network)  Bill (2010)  (Economics Legislation Senate Committee, 2011) [16] cited Victorian health system  238 
effectiveness and efficiency  evidence  provided  by Antioch (2010b) [17] in support of the new national arrangements.  239 
The Committee recommended that the Senate pass the Bill and recognized the Bill is 'a vital piece of legislation which 240 
will enable the implementation of significant elements of the health and hospital reforms agreed by COAG in April 241 
2010'. (Economics Legislation Senate Committee, 2011) [16].  More recently, various State governments are 242 
implementing  State Centres to facilitate best practice and innovation in NSW, Victoria and Queensland
2
. The 243 
methodologies in this paper and  deliberations of  more recent Senate Inquires in 2012,  2013  and 2016 outlined below 244 
could assist such State Centres along with  Australian governments, health services and the NHMRC.  245 
The  Senate Inquiries during 2012 into Palliative Care in Australia and  Factors Affecting the Supply of Health Services 246 
and Medical Professionals in Rural Areas addressed CPGs and the use of  health economics to improve efficiency, 247 
outcomes and  prioritization of health technologies and service delivery.   Stakeholders in  the Palliative Care Inquiry 248 
advocated urgent updated CPGs for palliative care, advanced care directives, dementia diagnosis,  pain management 249 
and case management to enable improvements in cost effective service provision and continuum of care.  Antioch 250 
recommended that CPG updates by COAG, Federal Department of Health and NHMRC could use CPGs  by NICE and  251 
Agency for Healthcare Research Quality (AHRQ) USA CPG Clearinghouse concerning opioids, advanced care 252 
directives/planning and radiotherapy.  She advocated that CEA evidence for new Australian CPGs in palliative care 253 
should be based on NHMRC methodologies (Antioch 2012a) [18].  The Senate report on Palliative Care in Australia 254 
recommended that  COAG should consider developing and implementing a case management model; and a uniform 255 
national palliative care pathway that clarifies when general palliative care moves into specialist palliative care, and 256 
maps the diagnosis and referral process to ensure that a palliative patient's journey involves coordinated access to all 257 
necessary services.  It also recommended that a national model legislation for advanced care planning should be 258 
developed  and the NHMRC should report  its work on alternative therapy claims in relation to palliative care and [19] . 259 
 260 
                                                          
2
 This includes the Agency for Clinical Innovation (ACI) and  Centre for Health Care Redesign in NSW and  the Centre for Health Care Improvement 
in Queensland. In Victoria the Commission for Hospital Improvement and the Health Innovation and  Reform Council were created. More recently 
the Victorian Commission wasdisbanded and replaced by Better Care Victoria 
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Stakeholders in the 2012 Rural Health Senate Inquiry argued for urgent mechanisms for  rapid  EBM translation of  261 
CEA evidence and CPGs into rural practice with the input of economists. They also advocated improved  Evidence 262 
Based Planning (EBP) to identify  rural supply and demand factors and prioritisation.  Antioch (2012b) [18] 263 
recommended that the Federal government undertake a national review of EBM translational work to prevent  264 
duplication, with a consolidated and rapid disseminate  EBM evidence to rural areas. For EBP she recommended the 265 
uptake of  evidence concerning disease burden, epidemiological data and CEA of interventions, for demand and supply 266 
modelling.  Any gaps in the evidence identified in the national review should  be addressed by  Federal and State 267 
governments, NHMRC and all  States  (Antioch 2012b) [20].  A key Senate Committee recommendation  was for the 268 
Department of Health and Ageing to  prepare a brief for COAG's Standing Council on Health on existing or emerging 269 
gaps affecting the delivery of health services to rural and remote communities caused by mis-alignment between 270 
Commonwealth and state policy, including options for measures to remediate such gaps [21].   271 
 272 
Antioch (2013b) [22] recommended to the 2013 Senate Inquiry on the Aged Care Quality Agency Bill 2013  that the 273 
Agency,  which is the new accreditation body,  should include health economists and indigenous health experts and 274 
should collaborate with  the NHMRC, GENI, Australian  Commission  on Safety and Quality  in Health Care 275 
(ACSQHC), Cochrane Collaboration, Guidelines International Network (GIN),  National Guideline Clearing House 276 
AHRQ, NICE, NHS Economic Evaluation Database (NHS EED), NHS Evidence, WHO Health Economics Network 277 
and the CDC.   That Committee considered five Bills on Aged Care of which the Quality Agency was one. The Senate 278 
Committee's Report  recommended  monitoring the impacts of fee scales on client welfare and providers, and new 279 
supplements for the homeless and workforce. The report addressed guidelines from the perspective of home care 280 
packages based on clinical need, accreditation of residential care services, workforce supplements and pricing [23]. 281 
 Under  the  April 2016  COAG Heads of Agreement, which cover public hospital funding from 2017 to 2020, the  282 
Commonwealth will provide $2.9b in additional funding but growth is capped at 6.5%  with some funding   linked to 283 
quality outcomes. The Agreements will  reduce  payments for specified adverse events, ineffective interventions,  284 
procedures known to be harmful and readmission rates and the Independent Hospitals Pricing Authority (IHPA) is 285 
working with the ACSQHC and COAG to develop implementation details [24], Antioch (2016a) [24]  recommended 286 
the risk adjustment of all comparative hospital data  to capture, inter alia,  the impact of state-wide referral services on 287 
case-mix severity and emphasised that reductions in funding can unfortunately further exacerbate adverse  quality 288 
outcomes for some conditions such as certain infections. The  Committee concluded that 'the gap in health and 289 
education funding remains. The Government remains committed to policies that deprive these areas of the  much 290 
needed funds'[25]. 291 
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In response to the Senate Select Committee on Health  Inquiry on  Health Policy, Administration and Expenditure  in 292 
2016 , Antioch (2016b) [26] recommended that, in conjunction with the COAG  2016  Health Agreements and 293 
associated ABF linking risk  adjusted quality outcomes to funding,  COAG should facilitate dissemination of   294 
NHMRC's methods for using the costs and benefits evidence in  CPGs Australia-wide  and the revised methods once 295 
finalised (Antioch, 2016b) [25].  The Inquiry recommended  that  the Government should determine that the  296 
implementation mechanisms for  ABF should  not be dismantled  and   a body similar to the National Health and 297 
Hospitals Reform Commission should be reconstituted ( Senate Select Committee on Health,  2016)  [27]    We now  298 
turn to the  NHMRC review of CPG development processes in Australia.. 299 
 300 
NHMRC review of Australian clinical practice guideline development and approval methodologies 301 
 302 
NHMRC is reviewing its CPG development and implementation methods, including the use of economic evidence and 303 
requested advice from GENI on use of the costs and benefits and socio-economic evidence. The advice was provided to 304 
the NHMRC  in  September  2013  and was based on the issues cited herein to 2013. More recent issues covered can 305 
further facilitate NHMRC's review which is still underway.  The NHMRC (2011) [28] 'Procedures and Requirements 306 
for Meeting the 2011 NHMRC Standard for Clinical Practice Guidelines document provides direction for CPG 307 
developers who must initially register  their  guidelines in the  NHMRC Development Register and include evidence 308 
about needs analysis, disease burden and the clinical problem to be addressed. NHMRC then notifies the Australian 309 
Health Ministers Advisory Council if CPGs have been accepted for consideration. The CPG drafts are assessed using 310 
the AGREE II tool. The CPG drafts are forwarded to the Therapeutics Goods Administration (TGA), Pharmaceutical 311 
Benefits Advisory Committee (PBAC), Medical Services Advisory Committee (MSAC) and Health Departments for 312 
comment.  The NHMRC's current review of its CPG processes and standards aims to improve development and 313 
implementation of CPGs, public health guidelines,  systematic reviews and decision making. This review involves 314 
NHMRC Principal Committees, NHMRC Synthesis and Translation of  Research  Evidence Advisory Group 2014-16 315 
with Working Groups formed from NHMRC's Research Translation Group  (RTG) Advisors List.  The current 316 
NHMRC standards (2011) [28] handbooks on CPGs (NHMRC, 1999, 2000a, 2000b, 2000c, 2001, 2002, 2009) [5,  6,  317 
7,  8,  9,  29, 30]  and methodological guidance by AHRQ and NICE will be considered.  The NHMRC (2011) [28]
 318 
Standards  refer to the publication 'NHMRC additional levels of evidence and grades of recommendations for 319 
developers of guidelines' (NHMRC 2009) [30]. However, NHMRC (2009) [30] does not address the economic 320 
evidence.  Rather, economic evidence is  only addressed in  'How to compare the costs and benefits: evaluation of the 321 
economic evidence (NHMRC, 2001) [9].  The NHMRC's (2011) [28] standards  state that the NHMRC desires  input on 322 
CEA of interventions to be included in guidelines. Hence, economic issues are important. NHMRC Standard C. 3.4 323 
11 
 
states the evidence review should involve  search strategies for cost effectiveness, and  resource implications of 324 
practice. NHMRC Standard D.9.2  indicates that guideline recommendations  should consider resource implications and 325 
cost effectiveness of  recommended  practice compared to current practice. NHMRC Standard G.4  indicates that 326 
resources for  guideline implementation should be considered. The NHMRC (2001) [9] handbook on how to  evaluate 327 
the economic evidence  uses Drummond et al’s “10 point” check list (Drummond et al, 2005) [11] and assesses whether 328 
there is a well-defined question,  a comprehensive description of alternatives is provided, effectiveness is established. 329 
all relevant cost and consequences are included along with appropriate measurement. It also assesses credible valuation, 330 
differential timing, incremental costs and consequences,  and whether allowance is made for uncertainty and appropriate 331 
interpretation of results (NHMRC, 2001) [9]. The matrix in table 1 is used to make decisions about the new technology 332 
given the strength of evidence for outcomes and costs [9]. The methods for the economic evaluation of health care 333 
programmes and treatments have also been  discussed  in the requirements of  other decision-making bodies, such as the 334 
National Institute of Health and Care Excellence (NICE) in the  UK, which uses the NICE Reference Case,  considered 335 
in more detail later. The reporting of economic evaluations of health interventions is challenging because substantial 336 
information must be provided to enable the scrutiny of findings.  Despite a growth in published reports in recent years, 337 
reporting guidelines have not being widely adopted. There has been a need to consolidate and update existing guidelines 338 
in a user-friendly manner. Checklists can assist peer reviews, authors, and editors, to  use consistent guidelines to 339 
improve reporting. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS statement 340 
consolidates and updates previous health economic evaluation guidelines into one current, useful reporting guidance.   341 
The ISPOR 2013 CHEERS 24 item check list, discussed more fully in the next section , can be used by the NHMRC, in 342 
conjunction with Drummond et al’s 10 point check list, when assessing the economic evidence.  A questionnaire by 343 
Antioch, Jennings, Botti et al (2002) [10] published in the European Journal of Health Economics, that scores 344 
Drummond et al  [11] 10 point check list,  has been  used  in Australia since 2000 to grade the cost effectiveness 345 
evidence using NHMRC methods and CEA thresholds for making recommendations about changes to clinical 346 
guidelines and for implementing  evidence in  three Victorian  Local Hospital Networks. Since 2013, that questionnaire 347 
[10] has been used in Australia in conjunction with CHEERS assessments which enables an in-depth analysis of issues 348 
covered in the Drummond's 10-point checklist. This work  on grading the CEA  evidence in systematic reviews  to 349 
evaluate CPGs for diseases such as diabetes type 2 and cystic fibrosis  involves  senior members  of  public and private 350 
hospitals, national associations, universities, and GENI's senior management team.   351 
 352 
 353 
 354 
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Table 1 Assessing CEA evidence using shadow prices in Australia: NHMRC [9] 
Ranking of evidence Ranking of evidence on effects 
on costs  High Low 
Strong  Recommend if: Recommend if 
  < $70,000 per life-year < $30,000 per life-year 
  Do not recommend if Do not recommend if 
  >$100,000 per life-year > $70,000 per life-year 
Weak  Recommend if Recommend if 
  < $30,000 per life-year < $30,000 per life-year 
  Do not recommend if Do not recommend if 
  > $70,000 per life-year > $30,000 per life-year 
    
 355 
We outline below international findings that can also guide NHMRC's review of  CEA thresholds  for CPG 356 
development and approval.  CEA studies should identify the health benefits offered by an intervention; the additional 357 
costs imposed on a limited healthcare budget; and the opportunity costs (i.e. health benefits forgone) from c ommitment 358 
of resources to an intervention. An intervention can be considered cost-effective if its benefits outweigh the opportunity 359 
costs of health benefits forgone. The opportunity costs in terms of forgone health benefits are reflected in most CEAs by 360 
using a cost-effectiveness threshold (CET) [33]. 361 
When the maximum acceptable trade-off between costs and effectiveness is known, CEA can inform whether a program 362 
providing a trade-off between its costs and its effectiveness should be implemented. By using the maximum WTP per  363 
Quality-Adjusted Life Year (QALY), one can establish a  decision rule for CEA. This view emanates from welfare 364 
economics, which states that welfare is maximized if goods are exchanged when there is a maximum WTP that exceeds 365 
the opportunity cost of the good (Polsky, 2005)  [31]  The  NHMRC (2001)defines its CEA threshold  or 'shadow 366 
prices' as is the predetermined maximum WTP for health gains [9]. 367 
CEA used by NICE is an assessment of whether the health expected to be gained from using a new medical technology 368 
exceeds the health likely to be forgone as other NHS activities are displaced to accommodate the additional costs of the 369 
new technology. The CEA threshold therefore represents an estimate of the health forgone as services are displaced 370 
[32].  371 
The challenge for decision makers is to determine and use CETs that reflect supply-side constraints. However, there 372 
are few empirically estimated supply-side CETs. One exception is Claxton et al (2015) [33] study that estimated the 373 
marginal productivity of the UK National NHS and produced a best estimate of the supply-side CET of £12,936, 374 
about half of UK GDP pc. [33] 375 
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Claxton et al (2015)  [33] estimated the effects of changes in NHS expenditure on the health of all NHS patients and 376 
found that NICE's  CEA threshold used  to assess new drugs is too high. The approval of new drugs is therefore causing 377 
more harm than good to NHS patents overall given the NHS is paying too much for new drugs.  NICE has applied   378 
£30,000 per QALY threshold to determine whether health benefits of a new drug are greater than the health likely to be 379 
lost because the additional resources required are not available to offer effective treatments to other NHS patients.   380 
Claxton et al (2015)  [33]  found that the  threshold is too high as their best empirical estimates, based on a number of 381 
assumptions, was £12,936   (rounded £13,000) of NHS resources adds one QALY to the lives of NHS patients.  Greater 382 
harm is therefore being done to other NHS patients when NICE approves costlier drugs. The approval of a new drug 383 
that costs the NHS an additional £10m per annum would offer benefits of 333 QALYs. It would also lead to the loss of 384 
773 QALYs for other NHS patients with increased mortality in circulatory, cancer, gastro-intestinal or respiratory 385 
diseases and reduced quality of life in mental health and neurological diseases. This represents a net loss of 440 QALY 386 
for every £10m of additional NHS costs.  Further, devoting £280m to the Cancer Drugs Fund in 2014/15 has been 387 
associated with  a loss of 21,645 QALYs for other NHS patients [33,  34].  388 
NHMRC (2001) [9] includes additional criteria  which allow higher prices  for CEA thresholds for criteria such as: 389 
quality of life for patient and/or family; survival improvement; functional status; condition is severe, rare, 390 
preventable, or leads to permanent effects in youth; no other health care options available and intervention prevents 391 
adverse flow-on effects into other sectors with equity implications. Health care options might require further 392 
consideration with regard to these social values if they fall in the range $70,000–$ 100,000 per life-year saved and 393 
rank highly for evidence on costs and effects, or if they are in the range $30,000–$70,000 per life-year saved and 394 
rank highly on one but not the other [9]. 395 
 396 
 Other developments about CEA thresholds in Australia are important to consider. Australia  has public insurance 397 
coverage for drugs through the Pharmaceutical Benefits Scheme (PBS).  Harris et al (2008) [35] found that the 398 
Pharmaceutical Benefits Advisory Council (PBAC) decided drug approval coverage from 1994  to 2004 without 399 
reference to a public CEA threshold for the cost per LYG or QALY.  WTP and decisions were based on the clinical 400 
significance, CEA results, cost to  government and disease severity.  Clinical significance increased the probability of  401 
recommending coverage by 0.21 and a drug for a 'life threatening' condition increased that probability by 0.38. 402 
Increases of $A10,000 from an incremental cost per QALY of $A46,400, reduced the  probability of listing by 0.06 403 
(Harris, 2008) [33].  Harris  et al (2016) [ 36 ]  analysed 1993 to 2009 PBAC funding decisions. They found that an  404 
A$10,000  increase in cost per QALY reduces  average probability of funding from 37%  to 33 %. For life threatening 405 
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conditions or where the drug has no active comparator, odds of positive recommendation are 3.18 and 2.14  greater. If 406 
both conditions are met, the odds are increased by 4.41  times [36]. 407 
 408 
 Shiroiwa, Sung and Fukuda  et al (2010) [37] note that although CEA thresholds for medical interventions are assumed 409 
to be $50 000-$100 000 in the US and 20 000- 30 000 UK pounds in the UK such values are unjustified, given  lack of  410 
evidence. They measured WTP for one additional QALY gained to determine the threshold of the incremental cost-411 
effectiveness ratio. They compared WTP for the additional year of survival in a perfect status of health in Japan, the 412 
Republic of Korea (ROK), Taiwan, Australia, the UK, and  USA. A double-bound dichotomous choice was used, and 413 
analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), 414 
NT$ 2.1 million (Taiwan), 23 000 UK pounds (UK), AU$ 64 000 (Australia), and US$ 62 000 (US). The discount rates 415 
of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% 416 
(US). They recommended a new classification of cost-effectiveness plane and methodology for decision making 417 
(Shiroiwa et al. 2010) [37]. 418 
Importantly, Drummond de Pouvourville, Jones, et al (2014) [38] note that NICE has developed supplementary 419 
guidance for  ‘end of life' therapies in the circumstance where the therapy is for a small patient population with life 420 
expectancy of  less than 24 months and where the therapy adds three months or more to life expectancy.  In this 421 
scenario,  QALYs gained should assume full quality-of-life in the added months. In addition, the Committee can 422 
consider that the QALYs gained should be weighted sufficiently high for the therapy to be approved, given NICE’s 423 
current threshold.  These findings along with Harris et al (2008, 2016) [35, 36], Shiroiwa et al (2010) [37] could inform 424 
NHMRC's consideration of revised thresholds for CEA in its review of CPG processes and in other countries. 425 
We now consider the CHEERS guidelines, which consolidate previous health economic evaluation guidelines. 426 
Requirements of other decision making bodies such as NICE, which uses the NICE Reference Case are also considered 427 
and may be instructive for deliberations of other CPG Agencies, including the NHMRC. 428 
 429 
Consolidated Guidelines for the Reporting of Economic Evaluations: The CHEERS Task Force  - Reporting 430 
Guidelines for Economic Evaluation 431 
 432 
 433 
The 'CHEERS Elaboration and Explanation Report of the ISPOR Health Economic Evaluation Publication Guidelines 434 
Good Reporting Practices Task Force' facilitates the use of the CHEERS statement by providing examples and 435 
explanations for each recommendation (Husereau, Drummond and Petrou, 2013) [39]. 436 
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If economic considerations are to be incorporated into clinical guidelines, the guidelines need to reflect the current 437 
knowledge on the cost-effectiveness methodology. Therefore, guideline developers need to consult the existing 438 
literature on economic evaluation of health care treatments and programmes. The methods for the economic evaluation 439 
of health care programmes and treatments have been discussed in the academic literature [11] and in the requirements 440 
of decision-making bodies, such as NICE in the  UK which uses the NICE Reference Case [40].The NICE Reference 441 
Case requires submission for product review to conform to the following standards: a decision problem  defined by 442 
NICE scope; comparator therapies listed in NICE scope; inclusion of all direct health effects for patients and caregivers; 443 
costs incurred by NHS and Personal Social Services (PSS), cost-utility analysis with full incremental analysis; time 444 
horizon long enough to reflect all important differences in costs and outcomes between technologies being compared; 445 
claims for health effects based on systematic review; health effects expressed as QALYs with EQ-5D the preferred 446 
instrument; data for health related quality of life measurement reported by patients and/or caregivers; preference data 447 
for valuation of changes in health related quality of life obtained from a representative sample of UK population; 448 
QALYs all have equal equity weight; resource use and costs valued using prices relevant to NHS and PSS;  costs and 449 
benefits should be discounted at same annual rate (3.5%)  (NICE, 2013 [40]; Langley, 2016) [42]. 450 
 451 
Application of these standards for chronic disease interventions involves modelling the natural disease progression and 452 
the impact of competing interventions over the patient’s lifetime or similar long-term time horizon. Disease progression 453 
stages can involve a Markov process to track a hypothetical cohort of patients through disease stages. Each health state 454 
is defined via associated utilities and costs, with results expressed as cost per QALY (Langley, 2016) [42]  The Markov 455 
process often involves two methods of evaluation.  Cohort simulation tracks a hypothetical cohort of patients 456 
simultaneously through the model. Monte Carl simulation randomly selects a patient from the cohort and each patient 457 
transits through the model one at a time (Drummond and McGuire, 2006) [43]  By application of a WTP threshold cost 458 
per QALY, products are judged acceptable, rejected or accepted after agreement on a the actual price set (Langley 459 
2016)[42].  460 
 461 
Although various aspects of the methods of economic evaluation are a continuing source of debate, there is much more 462 
agreement about the need for reporting standards for studies. That is, although different studies may use different 463 
methods, all researchers should have an obligation to report their studies in a transparent fashion. This will help 464 
guideline developers and other users of economic evaluations to benefit the most from the existing literature. The most 465 
recent attempt to specify reporting guidelines for economic evaluations is the CHEERS initiative [39]. 466 
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The CHEERS Standards were developed by the Good Research Practices Task Force established by the International 467 
Society for Pharmacoeconomics and Outcomes Research (ISPOR). The Task Force comprised specialists in the 468 
economic evaluation of health care programmes and the editors of journals publishing cost-effectiveness studies of 469 
health care interventions. The reporting guidelines were developed through a process consistent with that of the 470 
CONSORT initiative for developing guidelines for the reporting of clinical trials  [41]. 471 
The CHEERS guidelines  shown in Appendix 1  assess studies with regard to conflict of interest and funding sources in 472 
addition to  traditional components of published health economic evaluations  that involve the title, abstract, 473 
introduction, methods and discussion. Economic evaluation methods are assessed with regard to the target population 474 
and sub-groups, setting and location, study perspective, comparators, time horizon, discount rate, choice of  health 475 
outcomes, measurement of effectiveness and evaluation of preference based outcomes, estimates of resource and costs, 476 
currency, price date, conversions, choice of model, assumptions and analytic methods. Results are assessed in terms of   477 
study parameters, incremental costs and outcomes and characterising uncertainty and heterogeneity.  Research findings, 478 
limitations, generalisability and current knowledge are assessed in the study's discussion [41].  479 
One point to note is that, on occasions, the guidelines differ for economic evaluations conducted alongside a single 480 
clinical study (e.g. a clinical trial) and those conducted as part of a decision analytic model, involving the synthesis of 481 
data from a number of sources. Several issues arose during the development of the CHEERS guidelines. The main issue 482 
related to whether reporting guidelines should merely require the authors of a study to describe their methods, or 483 
whether authors should describe and explain why they had adopted a particular approach. A good example of this is the 484 
selection of comparators. The CHEERS group felt that, in addition to describing the comparators included in their 485 
study, authors should also give their rationale for the selection eg One rationale would be to include the current standard 486 
of care in the jurisdiction where the study was conducted [39] The CHEERS checklist enables detailed analysis of the   487 
items  in Drummond's  10 point checklist thereby facilitating  comprehensive scoring of Drummond's checklist using 488 
the EJHE questionnaire [10]  to  grade the evidence. 489 
Structuring Complex Evidence and Values Using Multi-Criteria Decision Analysis (MCDA)  490 
During the  1970s and 1980s there was debate in the economics and ethics literature about relevant criteria for making 491 
resource allocation decisions in health care. At that time the  focus  was on clinical and cost-effectiveness. During the 492 
subsequent two decades, health technology assessment bodies emerged. There was growing recognition that other criteria 493 
are important, relating to equity, acceptability, burden and sustainability.  More recently during the 2010s there has been 494 
growing interest in decision analytic methods for considering multiple criteria,  driven primarily by  NICE in the UK and 495 
shifts to Value-BasedPricing. MCDA is a methodology designed to help decision-makers when making complex choices 496 
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– first developed in the 1960s and 1970s (Peacock et al, 2013)  [44]. Health care decisions are complex and often 497 
involve trade-offs between c o n f l i c t i n g  a n d  multiple objectives. Decision making involving either 498 
committees or individuals can involve difficulty in  systematically evaluating all  the relevant information. The MCDA 499 
confronts trade-offs between alternatives under consideration and each decision maker prioritizes the most important. 500 
Where a group is involved, the priorities of decision makers can conflict, rendering  the decision-making process very 501 
complex. Reliance on informal processes during decision making  can result in  suboptimal decisions.  A formal process 502 
such as MCDA is therefore required   to evaluate alternatives and priorities to avoid inconsistency, variability, or a lack 503 
of predictability on the importance of specific factors or criterions in the decision. MCDA provides clarity on which 504 
criteria are relevant, their relative importance and how the information can be used in a framework for assessing 505 
available alternatives. It is  an extension of decision theory that covers any decision with multiple objectives (See 506 
Thokala et al,2016 [45] for a review). 507 
Whilst MCDA is used extensively in other sectors, recently health care applications have increased. During 508 
2014, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) established an 509 
MCDA Emerging Good Practices Task Force to establish a common M C D A approach in health care and 510 
develop assoc ia ted  good practice guidelines. MCDA is applied in various types of decision making in 511 
health care,  including beneﬁt risk analysis, health technology assessment, resource allocation, portfolio 512 
decision analysis, shared patient clinician decision making and prioritizing patients’ access to services. It 513 
allows for the inclusion of preferences and social values (Thokala, Devlin, and Marsh, et al 2016) [45]. 514 
 515 
MCDA Approaches 516 
MCDA approaches can be classiﬁed into value measurement models, outranking models, and reference-level 517 
models (Thokala and Duenas,  2012) [46]. 518 
 Value measurement models d e v e l o p  and compare numerical scores to determine the extent to 519 
which one decision alternative is preferred over another. They often involve additive models - 520 
"weighted-sum” models, or “additive multi-attribute value models”. These multiply a numerical 521 
score for each alternative on a specific criterion by the relative weight for the criterion and then 522 
sum those weighted scores to determine a “total score” for each alternative. 523 
 Reference-level modelling  searches for the alternative that is closest to attaining pre-deﬁned 524 
minimum levels of performance on each criterion, using linear programming techniques and 525 
a s p i r a t i o n  o r  g o a l  methods. 526 
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 Outranking methods make pair-wise comparisons of alternatives on each criterion which are 527 
combined to measure support for each alternative being judged the top-ranked alternative.  528 
Outranking algorithms include the Elimination and Choice Expressing Reality (ELECTRE) 529 
methods, Preference Ranking Organization Method for Enrichment of Evaluations 530 
(PROMETHEE), and geometrical analysis for interactive aid (GAIA) ( See Thokala, Devlin, and 531 
Marsh, et al 2016 for a review) [45]. 532 
Value measurement approaches are the most widely used approach in health care. However, 533 
determining which MCDA model is most appropriate depends on the analysis and decision maker 534 
preferences. (Thokala and Duenas, 2012) [46].  535 
Decision-makers in the health sector face a global challenge: how do we develop robust, evidence-based, scientific 536 
methods for priority setting? This challenge is often most evident in decisions concerning the coverage/reimbursement 537 
of new drugs and technologies.  Peacock, Mitton and Cromwell et al (2013) [44] indicated that a range of different 538 
criteria may be relevant for such decisions, including the effectiveness, cost-effectiveness and budget impact of the 539 
new drug; the incidence/prevalence and severity of the disease; the population group affected; the availability of 540 
alternative drugs/technologies; and, the quality of the available evidence [44]. 541 
When comparing new versus existing drugs/technologies these criteria will often need to be traded-off against one 542 
another. For example, a new drug may be more effective, but it may be costlier and targeted towards a smaller sub-543 
population. MCDA can assist decision-makers make trade-offs when resources are constrained.  When such trade-offs 544 
exist, MCDA offers a structured approach to evaluating and identifying a preferred option by scoring and weighting the 545 
various attributes and deriving an aggregate 'value'.  This is in contrast with more traditional committee based 546 
approaches, where trade-offs either not discussed or are explored in a more qualitative manner.   547 
 548 
Some key methodological issues and challenges identified by Peacock, et al 2013 [44].  There are two main stages 549 
associated with MDCA, i.e. problem structuring and model building. Problem structuring involves generating a set of 550 
alternatives and a set of criteria against which the alternatives are  evaluated and compared. Model building involves 551 
constructing some form of model which represents decision-makers’ objectives and their value judgements.  A key 552 
consideration  is  the methods used to describe decision-makers preferences and  'importance' weights for decision-553 
making criteria and the type of aggregation model used to combine criteria scores. 554 
 555 
 556 
 557 
 558 
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A simple model is: 559 
  560 
 561 
 562 
Equation 1 563 
 564 
Where: 565 
i = 1,…,n criteria 566 
wi = criteria weights 567 
j represents alternatives 568 
sij = scores for alternatives for different criteria 569 
WBS = Weighted Benefit Score 570 
 571 
 572 
Priority setting can be conceptualized as a continuous quality-improvement reiterative process involving the following 573 
sequential steps: define the aim and scope;  form an advisory panel of stakeholders;  establish a  program budget , 574 
develop the decision criteria;  identify  and rank options;  make decisions and specify the rationale; undertake a decision 575 
review process and finally, evaluate and improve.  The economic evidence and MCDA are applied at the decision 576 
criteria development stage through to decision making and rationale specification stage.  A review of the literature 577 
identified 52 different criteria listed in fourteen studies, with the most commonly occurring   criteria, in descending 578 
order, including accessibility, reducing inequalities, effectiveness, alignment with strategic plan and policies, value for 579 
money, affordability and integration with other programs.  Peacock, et al [44] compared criteria used in Australia and 580 
Canada for cancer control  and also for HTA agencies in Australia and  the UK.  These criteria are in Table  2 .        581 
Table 2: Criteria developed by Cancer Control and HTA Agencies 582 
 
Cancer Control initiatives 
 
National HTA Agencies 
National Cancer Control Initiative  ( Australia) 
 Health gain – Disability Adjusted Life Years 
(DALYs) 
 (Vertical) equity – reducing inequalities in 
mortality rates in vulnerable populations 
 Size of  health burden – disease burden in DALYs 
and cost to health system 
 Acceptability and feasibility 
 
 
 
NICE  (England and Wales) 
 
 Clinical effectiveness 
 Cost-effectiveness 
 Feasibility and impact 
 Equity and equality 
 Acceptability and appropriateness 
 
 
British Columbia Cancer Control decision-makers 
(Canada) 
 
 Health gain – Quality Adjusted Life Years 
(QALYs) 
 Resource impact – budget constraints 
 Resource impact – resource constraints 
 Availability/advisability of alternatives 
 
 
Pharmaceutical Benefits Advisory Committee 
(Australia) 
 
 Gap in current coverage 
 Cost-effectiveness 
 Effectiveness and safety 
 Community need 
 
 583 



n
i
ijij swWBS
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A review of the literature concerning criteria weights in MCDA methods found that  four studies did not report weights 584 
and seven studies used allocation of points (direct rating). Two studies used a combination of ratio estimation and direct 585 
rating. One  study used indifference methods (DCEs). Previous studies have also used swing weights (hybrid of 586 
indifference method). No studies have used gambles – all choices riskless  [44]. 587 
 588 
With regard to MCDA methods for aggregation rules, Peacock et al (2013) [44] found that where the aggregation rule 589 
was presented almost all (ie nine) applications used an additive functional form. Three did not state the functional form 590 
used. One used an exponential function and another used a variant of the multiplicative function.  Peacock et al (2013) 591 
found that the choice of functional form was rarely justified [44].  592 
MCDA is useful from several perspectives. The primary aim of MCDA is to develop models of decision-maker 593 
objectives and their value trade-offs so that alternatives under consideration can be compared with each other in a 594 
consistent and transparent manner. The process is often more important than the numbers. It involves value focussed 595 
thinking and values clarification. MCDA practice suggests preferences are constructed as part of the decision-making 596 
process, not endowed. It is consistent with deliberative-analytic methods. 597 
There are several issues that have arisen involving international consistencies and controversies in the decision criteria 598 
used in priority setting, the methods used to elicit criteria weights, and the complexity and transparency of the 599 
decision-making process.  These fall into four broad methodological challenges. Firstly, how do we decide which 600 
stakeholder's criteria will count - society, governments, private sector, patients, families, health providers,  or other 601 
decision-makers? Second, which methods should be used to elicit and describe decision-makers preferences, including 602 
the relationship between objectives and criteria. Further, the methods used to elicit importance weights for decision-603 
making criteria can be controversial along with the type of aggregation model used to combine criteria scores. 604 
 605 
Is there any common ground? Economics has often focussed on prescriptive behavioural rules, based on utility 606 
maximisation and game theory. On the other hand, psychology has sought to explain actual individual behaviour, and 607 
why it can deviate from prescriptive rules. Interestingly, decision analysis, including MCDA, endeavours to combine 608 
elements of both approaches through both 'prescription' with 'practicality'.  These approaches all share a common 609 
heritage from von Neumann and Morgenstern [44]. 610 
 611 
ISPOR's 2016 second Task Force report provides good-practice guidance on the implementation of 612 
MCDA for health care decisions. It incorporates a checklist to support the design, implementation and 613 
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review of an MCDA; guidance to support checklist implementation; the sequencing o f  i m p l e m e n t e d  614 
s t e p s  and describes the incorporation of budget constraints into an MCDA. It also covers the skills and 615 
resources, including software, required to implement MCDA; and canvasses future research directions. 616 
ISPOR's MCDA Good Practice Guidelines checklist is shown in table 3 below.  ISPOR al so  provides  617 
general guidance on the validation process in each step and on  how to implement the other 618 
recommendations in the checklist (Marsh, IJzerman and Thokala et al, 2016) [47]. 619 
 620 
 621 
Table  3  – ISPOR MCDA Good Practice 
Guidelines Checklist. 
 
1. Deﬁning the a. Develop a clear description of the 
decision  decision problem 
problem b. Validate and report the decision problem 
2. Selecting and a. Report and justify the methods used to 
structuring  identify criteria 
criteria b. Report and justify the criteria deﬁnitions 
c. Validate and report the criteria and the 
value tree 
3. Measuring a. Report and justify the sources used to 
performance  measure performance 
b. Validate and report the performance 
matrix 
4. Scoring a. Report and justify the methods used for 
alternatives  scoring 
b. Validate and report scores 
5. Weighting a. Report and justify the methods used for 
criteria  weighting 
b. Validate and report weights 
6. Calculating a. Report and justify the aggregation 
aggregate  function used 
scores b. Validate and report results of the 
aggregation 
7. Dealing with a. Report sources of uncertainty 
uncertainty b. Report and justify the uncertainty 
analysis 
8. Reporting and a. Report the MCDA method and ﬁndings 
examining of b. Examine the MCDA ﬁndings 
ﬁndings 
Source: Marsh, IJzerman and Thokala et al (2016) [47] 622 
 623 
Several areas for further research have been identiﬁed by  Marsh, IJzerman and Thokala et al (2016) [47] to 624 
address the challenges associated with the technique, including the level of precision required of an MCDA; 625 
the cognitive challenges facing different types of stakeholders and the support that can overcome these 626 
challenges; decision makers’ preferences for the theoretical foundations of MCDA methods; which 627 
value functions best describe stakeholders preferences; and the best methods for incorporating 628 
uncertainty and budget constraints into an MCDA. Further, constructing a cost-beneﬁt ratio using MCDA 629 
outputs faces several challenges. including the different scales  that are used to measure beneﬁts and costs. 630 
(Marsh, IJzerman and Thokala et al, 2016) [47] 631 
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 632 
Inclusion of Economic Evidence in Systematic Reviews:  Recommendations after reviews on health policy 633 
impact and best practices   634 
 Systematic reviews are important in improving understanding of comparative effectiveness and relative value of 635 
medical interventions in health policy decisions and  health guidelines (Niessen et al (2013) [48].  A study by the 636 
Hopkins AHRQ project team addressed the appropriateness of incorporating economic data into systematic reviews of 637 
medical interventions in America.  First, it examined if and how economic evidence impacts on health policy, including 638 
clinical guidelines,  in the USA.  It examined strengths and weaknesses of existing checklists used to assess best 639 
practices in economic evaluations. Finally, it reviewed studies addressing the use of economic outcomes in policy and 640 
decision making. The work is reported in publications by Niessen, Bridges and Lau et al (2012) [49]; Walker, Wilson 641 
and Sharma  et al (2012) [50] and Frick, Niessen, and Bridges  et al (2012) [51].   642 
 643 
The review on economic evidence impacts on policy including clinical guidelines, used original studies applying 644 
quantitative or qualitative methods providing empirical data, in any country.  The team excluded opinion or 645 
experienced-based articles without newly generated data. They defined ‘best-practice’ checklists as any original listing 646 
of recommendations that the authors used in economic evaluation. MEDLINE, EconLit, Cumulative Index to Nursing 647 
and Allied Health Literature (CINAHL), Embase®, and ISI Web of ScienceSM searched 1991 to January 2012.  The 648 
literature was searched for articles on economic evaluations, outcomes, and guidelines for the decision maker. Paired 649 
reviewers independently determined whether articles met eligibility criteria and then extracted data.  650 
 651 
Reviewers assessed the quality of each reporting study on policy impact using the standard grading recommendations 652 
(GRADE). Of 19,127 titles initially screened, 43 studies on policy impact were included, with all but five published 653 
since 2000. The most frequently studied countries were the United Kingdom (15), and Australia, Canada, and the 654 
United States (5 each). Most studies (27 studies) considered national-level policy and examined the key health actors 655 
involved. Important topics were reimbursement and health package decisions, and priority setting in programming. 656 
Thirty studies found evidence that use of economic evidence had a substantial impact on health care policy making, 27 657 
of which emphasized at least one other criterion, such as equity considerations, usually ill-defined (14 studies), clinical 658 
effectiveness, budget impact, ethical reasons, and advocacy arguments. The thirty studies confirmed the acceptance of 659 
economic evidence as having an impact on either general policy or specific decisions, such as reimbursement decisions.  660 
Of 37 observational studies on policy impact, 11 (30%) received a favourable rating on more than three of the 8 items 661 
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on the GRADE quality checklist. Five studies were graded of intermediate quality evidence (Niessen, Bridges, Lau  et 662 
al 2012) [49]. 663 
 664 
The study concerning best practices for conducting economic evaluations in health care was a systematic review of 665 
quality assessment tools (Walker, Wilson and Sharma et al (2012) [50]. The objective was to describe strengths and 666 
weaknesses of checklists for conducting and reporting on economic evaluations in health care. The authors defined 667 
checklists as the original listings of specific items recommended in the conduct or reporting of an economic evaluation. 668 
The study involved a review of  the criteria for judging that an economic evaluation is of sufficiently high quality to be 669 
useful. It also considered the importance of different aspects of the evaluation; and the extent to which high quality on 670 
one aspect of an evaluation can compensate for lower quality items. The methods involved a systematic search until 671 
January 2012 for articles and guidelines for decision makers. In MEDLINE, EconLit, CINAHL, Embase, and ISI Web 672 
of Science.   They found that ten peer-reviewed journal articles reported an original checklist. The first in 1992 and last 673 
in 2011 (EVEREST and CHEERS in 2013). The number of items ranged from 11 to 57. Perspective was a criterion in 674 
all 10.  The ten checklists reviewed included those by  Adams, 1992.  Gerard, 1992.  Sacristan, 1993,  Clemens, 1995. 675 
The U.S. Panel, The British Medical Journal (BMJ) Checklist, The Paediatrics' Quality Appraisal Questionnaire 676 
(PQAQ). The Quality of Health Economic Studies (QHES) List.  The Consensus on Health Economic Criteria (CHEC) 677 
List.  and A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions. (Grutters, 678 
2011).[52-62]. 679 
Eleven criteria were in 7 to 9 lists:  including target population, alternatives, study question, design, measurement, 680 
valuation, outcome identification, outcome measurement, time adjustment, sensitivity and uncertainties, presentation of 681 
results, generalizability, and incremental analysis. Four had evidence of excellent test-retest reliability: none had 682 
evidence of excellent inter-rater reliability in two or more studies. Three had evidence of excellent criterion validity, 683 
comparing checklists or expert ratings. They concluded that several well-developed checklists exist for investigators, 684 
reviewers, and journal editors to use in efforts to ensure more informative and transparent evidence (Walker, Wilson 685 
and Sharma et al (2012)[50]. 686 
 687 
They also analysed the usefulness of economic evaluation data in systematic reviews of evidence (Frick, Niessen, 688 
Bridges et al 2012). [51]  This addressed the question:  How useful is incorporating economic evaluation data into 689 
systematic reviews of medical interventions? The method used was a consensus process with outside experts to develop 690 
a conceptual framework.    691 
 692 
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They found that all stakeholders, including insurers  are interested in economic data and the perspectives of patients, 693 
providers, and manufacturers. Patients and providers determine the demand for care and manufacturers determine the 694 
supply.   Decisions are to be based on incremental cost, magnitude of the incremental effect, and the probability that 695 
economic evidence will change a decision. There is a high priority for evidence if there is a small effect at a high level 696 
of expenditure with a high probability of influencing a decision. 697 
 698 
 Economic data are of interest at many policy levels including approval and monitoring of services, formulary inclusion, 699 
insurance coverage, reimbursement rate, preferred practice guideline, technology adoption or non-adoption, or clinical 700 
management. They may include information on cost-effectiveness, productivity changes related to disease, price data, 701 
responses to price changes.  The following areas were of greatest interest: demand for care: time, distance, innovation 702 
price, price sensitivity, substitutes and complements, WTP, absenteeism and presentism. Supply of care was of interest 703 
including economy of scale, efficiency changes and return on investment. The equity  and  efficiency measures of 704 
particular interest were cost of illness studies; disease burden, Quality of life, budget impact, CEA ratio, net benefits 705 
and disparities.  Existing economic data may be sufficient. Occasionally, it may be necessary to perform new 706 
evaluations in case of inadequate data (Frick, Niessen, Bridges et al 2012) [51]. 707 
 708 
Conclusion 709 
There is some evidence that Drummond's 10-point checklist [11], when used in conjunction with Antioch et al's [10] 710 
questionnaire that scores Drummond's checklist, has resulted in cost-effective health care. These were used to grade 711 
economic evaluations, while integrating economic evidence into CPGs by the Australian  Local Hospital Networks that 712 
use both NHMRC and international  methodologies.  That checklist and questionnaire can be used, in conjunction  with 713 
the CHEERS 24 item checklist by health services, governments, NHMRC, other CPG organisations,  and the ACSQHC 714 
for grading the  economic evidence.  Whilst the ten checklists reviewed by AHRQ are very useful, their limitations of 715 
inter-rater reliability can  be addressed by including more than one assessor to reach a consensus on assessments. 716 
especially when impacting on treatment decisions. Further research could assess the impact  of such checklists on the 717 
cost effectiveness of health services where they have been used to assess evidence for CPGs and  treatment decisions. 718 
Antioch et al's [10] questionnaire involves consensus by two assessors, given the impacts on treatment decisions. The 719 
issues discussed concerning  CEA thresholds,  decision rules,  opportunity costs, WTP and end of life therapies are also 720 
instructive world-wide.  Priority setting is important and  where trade-off decisions between criteria are required and 721 
MCDA is  useful  for Evidence Based Medicine and Evidence Based Planning. The Hopkins review identifies key 722 
priority areas for studies including the  demand for care issues which can investigate time, distance, innovation price,  723 
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price sensitivity, substitutes and  complements, WTP,  absenteeism and presentism. Supply of care  issues can explore 724 
economies of scale, efficiency changes, and return-on-investments, equity and  efficiency measures can include cost of 725 
illness studies,  disease burden, quality of life, budget impact, CEA ratios, net benefits and disparities.   726 
COAG, AHMAC, IHPA, ACSQHC and the Australian Department of Health could expedite the Australia-wide 727 
dissemination of  NHMRC's methods on using the costs and benefits in CPGs and the subsequent revised methods. This 728 
may assist the health industry prepare for implementation of COAG’s 2016  Heads of Agreements on Public Hospital 729 
Funding which reduces ABF for specified adverse events, ineffective or harmful treatments and  readmissions from  730 
July 2017.     IHPA, ACSQHC and COAG can risk adjust ABF and quality outcome measurement, through analysis of 731 
complexity markers for  state-wide referral services such as transplantation, major trauma and cystic fibrosis. to enable 732 
equity. 733 
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